Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Lexagene Holdings Inc LXXGQ

Healthcare Medical Devices
Lexagene Holdings Inc. is a molecular diagnostics company engaged in researching, developing and commercializing automated genetic analyzer devices in clinical and life science industries. The Company is focused on developing molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, and for use in open-access markets such as food and water safety, clinical research, agricultural testing and biodefense. The Company's MiQLab System is an automated, open-access molecular diagnostic system for pathogen detection, allowing users to test for multiple pathogens onsite, returning results in approximately 2 hours. Its MiQLab System is an automated, multiplexing polymerase chain reaction (PCR)-based system designed for syndromic testing in human clinical diagnostics and veterinary diagnostics, as well as food safety testing, and open-access custom testing markets.


GREY:LXXGQ - Post by User

Lexagene Holdings Inc
Bullboard Posts
User Avatar Image
(9)
•••
Comment by Ventor12on Nov 27, 2018 12:08pm
123 Views
Post# 29027737

RE:RE:RE:RE:RE:Nice Drop

RE:RE:RE:RE:RE:Nice DropDaryl (the president, not CEO) has said a couple times that he expect offers on the company. He even said that he anticipated a offer before October/November. If a buy out were to happen, it would have happened in a proper way, remember that insiders own quite a bit. I've seen and read interviews from two years back, and back then they stated that they would be ready to commercialise the LXG by end of 2018. Now it looks like they are aiming to be on the market by 2019. The LXG is all the company have, and they will have to raise a lot of money going into the commercialising phase. I think the selling pressure is people who don't want to wait and get caught in a financial raise. If bigger companies truly is interested in LexaGene and its technology, then now is a great time to make a bid on the company. 

Jack have said that he believes that LexaGene could be valued in the $300-$400 million range in 2-3 years, and that is also what their competitors have been acquired for. I'm awaiting more information from the company, they also said that data would be out in October. Haven't seen it yet.


Bullboard Posts
Dealroom for high-potential pre-IPO opportunities